Chester County News and Community Website
PHILADELPHIA, PA — Passage Bio, Inc. (Nasdaq: PASG) has shared its financial results for the first quarter of 2025, along with updates on its ongoing clinical programs and operational advancements. …
Passage Bio Reports Q1 2025 Financial Results and Highlights Progress in Gene Therapy Development Read More PHILADELPHIA, PA — Passage Bio, Inc. (NASDAQ: PASG) announced its 2024 financial results, highlighting progress in its PBFT02 gene therapy program for frontotemporal dementia (FTD) associated with GRN mutations (FTD-GRN) …
Passage Bio Reports 2024 Financial Results and Advances in PBFT02 Program Read More PHILADELPHIA, PA — Passage Bio, Inc. (NASDAQ: PASG) has announced its participation in two upcoming investor conferences, where management will share updates on the company’s progress and engage with stakeholders.
Passage Bio to Present at Two Major Investor Conferences Read More PHILADELPHIA, PA — Passage Bio, Inc. (Nasdaq: PASG) has shared updated findings from its ongoing Phase 1/2 upliFT-D clinical trial, which evaluates PBFT02 as a potential treatment for frontotemporal dementia …
Passage Bio Reports Promising Data in Trial for Frontotemporal Dementia Treatment Read More PHILADELPHIA, PA — Passage Bio, Inc. (Nasdaq: PASG) this week reported its third quarter financial results for 2024, highlighting substantial progress in its PBFT02 gene therapy program for frontotemporal dementia …
Passage Bio Advances PBFT02 Gene Therapy Program Amidst Positive Q3 2024 Results Read More PHILADELPHIA, PA — Passage Bio, Inc. has unveiled promising interim data from its ongoing global Phase 1/2 upliFT-D clinical trial at the 14th International Conference on Frontotemporal Dementias (ISFTD2024). The study …
Passage Bio Shares Promising Data on PBFT02 for Frontotemporal Dementia Read More PHILADELPHIA, PA — Passage Bio, Inc. (Nasdaq: PASG) has announced the appointment of Tom Kassberg to its Board of Directors, along with his role on the Audit Committee, marking a significant …
Passage Bio Welcomes Tom Kassberg to Board, Aiming to Strengthen Strategic Vision Read More PHILADELPHIA, PA — Passage Bio, Inc. (Nasdaq: PASG) released its financial results for the second quarter ended June 30, 2024, along with significant business highlights.
Passage Bio Reports Q2 2024 Financial Results and Business Updates Read More PHILADELPHIA, PA — Passage Bio, Inc. (NASDAQ: PASG) has announced a series of agreements to out-license its three clinical-stage pediatric lysosomal storage disease programs to GEMMA Biotherapeutics, Inc. (GEMMABio). The …
Passage Bio Out-Licenses Rare Disease Programs to GEMMA Biotherapeutics Read More PHILADELPHIA, PA — Passage Bio, Inc. (NASDAQ: PASG) announced positive feedback from the U.S. Food and Drug Administration (FDA) on its proposal to evaluate PBFT02 for treating frontotemporal dementia (FTD) …
Passage Bio Receives FDA Support for Expanding Dementia Treatment Trial Read More